NCT05430386 2023-02-14
Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1 Unknown
Clinical Trials
5 trialsNCT02981108 2023-01-23
A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1/2 Unknown
NCT03849768 2023-01-20
A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT05223595 2022-02-04
A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLC
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT04951648 2021-07-07
A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3 Unknown